Product Information
TRI-BUFFERED ASPIRIN 325 MG TB is a generic product labeled by Major Pharmaceuticals, priced at $0.0207 per EA under NDC 00904201559. Its NADAC has been published 666 times since Nov 28, 2013.
Strength
325 mg/1
Manufacturer
Major PharmaceuticalsNDC
00904201559
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
6/17/2026
Active Ingredients
ASPIRINApproval Type
OTC MONOGRAPH DRUG
FDA Application
M013On Market Since
3/30/1990
Pharmacological Classes
Price Statistics
The NADAC for TRI-BUFFERED ASPIRIN 325 MG TB has been published 666 times since Nov 28, 2013, and over the history we have for it it has risen 13.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0207 per EA |
|---|---|
| All-time high | $0.0225 (Mar 14, 2018) |
| All-time low | $0.0163 (Feb 19, 2014) |
| 52-week high | $0.0207 |
| 52-week low | $0.0198 |
| Median price | $0.0189 |
| Average price | $0.0190 |
| Largest weekly change | +17.9% (Feb 21, 2018) |
| Weeks tracked | 666 |
| Tracking since | Nov 28, 2013 |
1W
N/A
1M
N/A
3M
0.0%
6M
+2.5%
1Y
+2.2%
3Y
+9.1%
5Y
-1.6%
All
+13.1%
Last surveyed Aug 26, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 42% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Major Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aspirin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI-BUFFERED ASPIRIN 325 MG TB?
The current National Average Drug Acquisition Cost (NADAC) for TRI-BUFFERED ASPIRIN 325 MG TB, manufactured by Major Pharmaceuticals, is $0.0207 per EA (NDC 00904201559), effective Aug 26, 2026.
How has the price of TRI-BUFFERED ASPIRIN 325 MG TB changed over time?
Over the history we have for it, the NADAC for TRI-BUFFERED ASPIRIN 325 MG TB has risen 13.1%. It has been tracked across 666 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRI-BUFFERED ASPIRIN 325 MG TB?
Since Nov 28, 2013, the NADAC for TRI-BUFFERED ASPIRIN 325 MG TB has ranged from a low of $0.0163 (Feb 19, 2014) to a high of $0.0225 (Mar 14, 2018), with a median of $0.0189 per EA.
Are there cheaper alternatives to TRI-BUFFERED ASPIRIN 325 MG TB?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QC ASPIRIN 325 MG TABLET, is $0.0121 per EA — about 42% below TRI-BUFFERED ASPIRIN 325 MG TB.
Who manufactures TRI-BUFFERED ASPIRIN 325 MG TB?
TRI-BUFFERED ASPIRIN 325 MG TB (NDC 00904201559) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.